Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare, inherited disorder in which severe deficiency of ADAMTS13 permits unusually large von Willebrand factor multimers to persist. These multimers bind platelets and can form microthrombi in small vessels. The resulting platelet consumption, haemolysis and organ injury can become rapidly life-threatening. Recombinant ADAMTS13 (rADAMTS13; marketed in the United States and European Union as Adzynma) replaces the deficient enzyme and is used as enzyme replacement therapy (ERT) for prophylaxis or, depending on the local authorisation, on-demand treatment of acute episodes.[1,2]

A safety question has emerged after marketing: some treated patients have developed antibodies that neutralise ADAMTS13 activity. If inhibitory antibodies reduce the activity of infused rADAMTS13, a patient may receive treatment without achieving the expected biological effect. The clinical consequence is potentially more than a laboratory abnormality. Failure to restore enzyme activity can permit recurrent TTP manifestations, with serious outcomes including death reported to FDA. In September 2026, FDA approved a boxed warning for the US product label and required monitoring of ADAMTS13 activity and neutralising antibodies.[3,4]

This issue also illustrates an important distinction in biologic safety surveillance. A positive anti-drug antibody (ADA) test does not automatically mean that treatment has failed. Binding antibodies can be detected without measurable neutralisation or clinical effect. Neutralising antibodies, sometimes termed inhibitors, are a functionally important subset. Assay design, baseline endogenous antibodies, previous plasma exposure, the timing of sampling and the rarity of cTTP all affect what can be inferred from a report.

Scope and Regulatory Context

This article examines immunogenicity-related loss of effect with rADAMTS13 in cTTP from a pharmacovigilance perspective. It explains the biological rationale, separates clinical-trial findings from post-marketing evidence, compares the current US and EU product information, and sets out an operational approach to case evaluation and signal governance. It does not provide treatment advice. Decisions about testing, treatment continuation, rescue therapy or alternatives belong to the treating specialist using current local product information and the patient's clinical circumstances.

The regulatory position is jurisdiction-specific. The US Prescribing Information revised in September 2026 carries a boxed warning that neutralising antibodies to ADAMTS13, with serious outcomes including death, have been reported after Adzynma. It states that neutralising antibodies may reduce or eliminate response to recombinant or plasma-derived ADAMTS13, and that all patients should be monitored for ADAMTS13 activity and neutralising antibodies before starting and periodically during treatment.[3] The FDA-approved US language applies in the United States; it does not itself amend European product information.

The European Commission-authorised product information, updated on the European Medicines Agency (EMA) site on 2 October 2026, describes the potential for antibodies to rADAMTS13 to decrease response. It says that if such antibodies are suspected and there is lack of efficacy, other therapeutic strategies should be considered. The patient leaflet refers to neutralising antibodies as inhibitors that could make treatment stop working properly. The EU SmPC reports that ADA were very commonly detected but states that no effect on pharmacokinetics, efficacy or safety was observed in the available data, which remain limited.[2] As of the date of this review, the published EU product information does not contain the September 2026 US boxed warning or the same explicit all-patient baseline and periodic testing instruction.

These differences should be represented accurately in safety documents, training and responses to healthcare professionals. A global safety database can capture cases from all territories, but expectedness, label compliance and regulatory actions must be assessed against the applicable local reference safety information (RSI) and current procedural status. A US warning must not be described as a global requirement; equally, the absence of identical EU wording does not make a serious biologically plausible report irrelevant to EU signal evaluation.

Disease Biology and Therapeutic Rationale

ADAMTS13 is a plasma metalloprotease that cleaves large and ultra-large von Willebrand factor (VWF) multimers into smaller units with less platelet-binding activity. In cTTP, biallelic pathogenic variants in ADAMTS13 cause a severe inherited deficiency. Without sufficient enzyme, ultra-large VWF multimers persist and promote platelet-rich microvascular thrombi. Platelet consumption produces thrombocytopenia, while shear-related red-cell injury causes microangiopathic haemolytic anaemia. Neurological, renal, cardiac and other organ manifestations may accompany an acute episode.[1,2]

rADAMTS13 is a recombinant form of the human enzyme. Replacement can restore circulating ADAMTS13 activity and support VWF processing. Unlike an intervention that blocks a downstream clinical symptom, replacement aims to correct the deficient enzymatic function underlying cTTP. This explains why measured enzyme activity is clinically informative and why an antibody that inhibits ADAMTS13 may undermine the core therapeutic mechanism.

The same biology requires care in interpreting an apparent breakthrough episode. cTTP itself can produce thrombocytopenia, haemolysis and organ-specific symptoms. A TTP event during treatment may reflect inadequate dose or interval for that patient, missed or delayed doses, an intercurrent trigger, an alternative diagnosis, or reduced response associated with neutralising antibodies. Temporal association with treatment is not enough to identify which explanation applies. A useful assessment combines exposure and administration history with ADAMTS13 activity, the clinical course and any available inhibitor testing.

Antibody Categories and Clinical Meaning

Immunogenicity testing typically seeks to detect binding antibodies to a therapeutic protein and may include additional methods to characterise their function. A binding ADA result indicates that immunoglobulin has bound a test reagent under the assay's conditions. By itself, it does not establish that the antibody neutralises enzyme activity, accelerates clearance, causes hypersensitivity or has any measurable effect on clinical outcomes.

Neutralising antibodies are detected through functional assays designed to determine whether patient immunoglobulin inhibits the biological activity of ADAMTS13. In this context, such antibodies are also described as inhibitors. They are clinically consequential because diminished enzyme activity could compromise replacement therapy. The relationship between antibody titre, duration, measured enzyme activity and clinical loss of effect requires product-specific evaluation; one positive test should not be treated as proof that every subsequent dose will fail.

Other immune findings must remain conceptually separate. Hypersensitivity reactions may be immune-mediated, but an allergic reaction does not establish neutralising antibodies. Antibodies to host-cell proteins or other product-related impurities, if studied, are not equivalent to antibodies against ADAMTS13 itself. Likewise, pre-existing autoantibodies against endogenous ADAMTS13 may be present in acquired immune-mediated TTP, a different condition from inherited cTTP. Diagnostic context and assay specificity matter when a result is interpreted.

In cTTP, the intended replacement protein closely resembles the endogenous enzyme. An assay that detects anti-ADAMTS13 activity may be unable to determine whether the antibody arose after exposure to recombinant product, whether it was already present against endogenous ADAMTS13, or whether it cross-reacts with both. FDA's initial investigation described limitations in distinguishing antibodies directed to recombinant ADAMTS13 from antibodies to endogenous ADAMTS13 in the reported fatal case.[4] This creates a real causality limitation: the antibody may be clinically relevant without the evidence proving that rADAMTS13 induced it de novo.

Clinical Evidence and the Limits of Pre-Authorisation Data

The pivotal evidence base is necessarily small because cTTP is rare. The principal phase 3 study was an open-label, randomised, active-controlled crossover study with prophylactic treatment periods followed by an rADAMTS13 continuation period. A final analysis published in September 2026 reported results from 48 participants; the trial remains small for detecting rare immunogenicity outcomes.[7,8] The US label describes 46 randomised patients in the prophylaxis cohort; the EU product information reports 45 evaluated in that cohort and 44 entering the continuation period. These populations differ by analysis and regulatory document, so a single “trial size” should not be repeated without specifying its denominator.[2,3]

The study compared rADAMTS13 with plasma-based therapies over six-month periods. Acute TTP events were uncommon: the EU EPAR reports one acute event in the plasma-based treatment period and none in the rADAMTS13 period, a count too small to establish a precise comparative effect on acute events. Other disease manifestations were also assessed. The study supports the replacement therapy's clinical rationale, but its size and duration cannot exclude very rare, delayed or treatment-emergent immunogenicity outcomes.[1,2]

The immunogenicity findings require precise wording. The September 2026 US label reports low-titre binding antibodies to ADAMTS13 in 13 of 67 prophylactically treated patients across the clinical trials, with no observed clinical impact on safety or efficacy and no increase in titres over time. No cTTP trial participant tested positive for neutralising antibodies. All trial participants had previously been exposed to ADAMTS13 through plasma-based products, and FDA states that there are no immunogenicity data for patients naïve to plasma-based products.[3] The label also cautions that observed ADA incidence depends on assay sensitivity and specificity and that results from different assay methods cannot be compared meaningfully.

Those findings do not establish that post-marketing neutralising antibodies are impossible. A trial can contain binding ADA without neutralisation, and a trial with a few dozen evaluable participants has limited ability to detect a rare event. Clinical trials may also have shorter exposure, narrower inclusion criteria and more structured observation than routine care. Conversely, a post-marketing report of an inhibitor after exposure does not alone prove that the therapeutic protein caused it. Both evidence streams matter, but they answer different questions.

From Safety Reports to Regulatory Action

FDA issued a Drug Safety Communication on 21 November 2025 describing an investigation into a reported death involving neutralising antibodies to ADAMTS13 after Adzynma treatment for cTTP.[4] The patient was a child who had a history of severe allergic reactions to fresh frozen plasma (FFP). FDA described progressive neurological symptoms and identification of neutralising antibodies approximately ten months after prophylaxis began. The communication noted that neutralising antibodies had not been reported in the cTTP clinical trials and explained that the then-available testing could not distinguish antibodies to recombinant ADAMTS13 from those against endogenous ADAMTS13.

This account is a safety communication about a serious report under investigation, not a controlled causal estimate. Prior FFP reactions are medically relevant to the patient's treatment context, but they do not establish the mechanism of the antibody finding. The interval between treatment initiation and antibody detection supports the need to consider delayed immunogenicity, but timing alone cannot identify the antibody's origin. The distinction between “reported after treatment” and “caused by treatment” should remain visible in case narratives and signal assessments.

FDA subsequently initiated a safety-labeling change process under section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act. In its May 2026 Safety Labeling Change Order, FDA concluded that serious outcomes, including death, associated with neutralising antibodies constituted new safety information and directed the manufacturer to add a boxed warning and revise warnings and patient information.[5] The order stated that neutralising antibodies could decrease or eliminate response to recombinant or plasma-derived ADAMTS13 and required monitoring of all patients for ADAMTS13 activity and inhibitors.

On 23 September 2026 FDA approved the supplemental biologics licence application with the boxed warning and related label updates.[3,6] The warning describes serious outcomes including death and calls for close monitoring of all patients. The detailed warning directs measurement of ADAMTS13 activity and neutralising antibodies before initiation and periodically throughout treatment, including for patients previously exposed or naïve to plasma-based products.[3] The label does not prescribe a fixed testing interval; the article should not invent one. FDA's safety communication also tells patients not to stop treatment without speaking to their healthcare professional. Safety communication should preserve that advice: a warning about a serious potential loss of response is not an instruction for patients to discontinue a medicine abruptly.[6]

FDA also determined that spontaneous reports alone would not be sufficient to assess the risk. The labeling order required a prospective, multicentre interventional trial to assess immunogenicity and clinical loss of efficacy, and a non-interventional real-world safety study with at least 12 months of follow-up.[5] This is a regulatory requirement specific to the US approval and signal. It illustrates that case reports can justify risk action while leaving important questions—frequency, predictors, mechanism, clinical course and assay performance—to be addressed through structured study.

Regulatory Status and Product Information: United States and European Union

The US warning is a boxed warning, the most prominent warning in FDA labelling. It advises that neutralising antibodies to ADAMTS13 have been reported with serious outcomes including death, may cause a decreased or absent response to recombinant or plasma-derived ADAMTS13, and require monitoring of all patients for activity and neutralising antibodies.[3] The full Prescribing Information further notes that antibody effects on rADAMTS13 pharmacokinetics and pharmacodynamics are unknown and that the risk in plasma-naïve patients is also unknown because there are no data in that population.[3]

The EU SmPC also acknowledges the potential for antibodies to rADAMTS13 to decrease response. It states that antibodies were very commonly detected in clinical data but no effect on pharmacokinetics, efficacy or safety was observed in the limited dataset.[2] Its current language says to consider other therapeutic strategies if antibodies are suspected and lack of efficacy occurs. The patient leaflet warns that neutralising antibodies (inhibitors) may make treatment stop working properly. This is meaningful product information, but it is not the same as the newer FDA boxed warning or FDA's explicit monitoring direction.

The EMA's Adzynma page indicates an EU marketing authorisation under exceptional circumstances, with further data requirements and annual review; the medicine is also subject to additional monitoring.[1] The authorisation reflects the rarity of cTTP and the limited number of acute events available for study. Those regulatory features do not establish an antibody signal, but they reinforce why post-authorisation evidence and ongoing review are important.

A pharmacovigilance organisation should maintain a dated, territory-specific view of this information. Regulatory intelligence should distinguish: (1) an authority's safety communication; (2) a legally directed labelling change; (3) the approved local label; and (4) a pending or required study. A label change in one jurisdiction does not immediately change RSI in another. Case seriousness and expedited-reporting decisions follow applicable regulations, while expectedness should be judged against the current local reference text and reporting framework.

Why This Is a Pharmacovigilance Safety Issue

Loss of efficacy is not always framed as a safety outcome, yet in a disease where untreated enzyme deficiency can lead to acute microvascular thrombosis, failure of replacement may expose a patient to direct harm. The clinically important event is not merely antibody detection. It is the sequence in which an antibody finding is associated with reduced enzyme activity, inadequate response, disease recurrence, rescue treatment, organ injury or death.

That sequence may be incomplete in an individual report. The reporter may only know that a patient deteriorated; test results might be pending or unavailable. A suspected loss-of-effect case with a serious cTTP exacerbation should therefore be assessed on the available clinical facts and followed up. Do not wait for an inhibitor titre to process a valid report, submit a required case or escalate an urgent risk. Conversely, do not recode every detectable binding antibody as neutralising or as an adverse reaction with clinical consequence.

For signal management, antibody detection, low ADAMTS13 activity, breakthrough cTTP manifestations and reduced response can be analysed as related but non-identical evidence. A useful review asks whether the reports share compatible timing, phenotype, laboratory profile, dose history and outcome; whether assay methods are comparable; whether patients had prior plasma or other ADAMTS13 exposure; and whether alternative clinical explanations exist. The pattern may support a safety signal even if the denominator and precise causal pathway are unknown.

Case Intake and Follow-Up

A report may arrive as an acute cTTP exacerbation, a laboratory finding, an apparent loss of response, or an antibody result from a routine follow-up assessment. Intake should preserve the reporter's terminology while clarifying what is actually known. A case narrative that states “neutralising antibodies caused treatment failure” is not supported if the source only reports a positive binding ADA test and falling platelets. The record should separate reported diagnoses, measured laboratory values, suspected mechanism and MAH medical assessment.

A focused data set supports both individual patient assessment and aggregate signal evaluation:

Follow-up should be targeted, proportionate and sensitive to urgency. If the report describes neurological deterioration or suspected acute TTP, clinical care must not wait for pharmacovigilance follow-up. The safety team can request test results, dosing history and outcome in parallel with required reporting and internal escalation. Where a functional inhibitor assay is not available or was not performed, record that limitation; do not convert missing data into a negative result.

Laboratory findings should be recorded with sample date, relation to the most recent dose, assay name or method where known, units, reference range and the laboratory's interpretation. A value without this context can be difficult to compare across cases or time points. Where repeated results exist, preserve their sequence. A single low activity measurement may reflect timing, disease status, assay variability or neutralisation and should not be interpreted without clinical context.

Causality Assessment

Causality assessment is a structured evaluation of whether the totality of evidence supports a relationship; it is not a mechanical score. For rADAMTS13-associated neutralising antibodies, the biological plausibility is strong: inhibition of the replacement enzyme could lower functional activity and permit the cTTP mechanism to re-emerge. FDA's post-marketing reports and regulatory action establish that this risk has been reported and judged serious enough to warrant a US boxed warning. They do not provide an incidence estimate or prove product causation in every individual case.[3-6]

A transparent individual assessment considers several dimensions:

• Temporality: When did treatment start, when was antibody testing performed, and when did enzyme activity decline or clinical deterioration begin? Delayed detection is plausible but does not prove antibody induction.
• Functional evidence: Was a neutralising assay positive, or was only binding ADA detected? Were titre, method, cut-off and confirmation reported? Can the assay distinguish antibodies directed at endogenous and recombinant ADAMTS13?
• Pharmacodynamic coherence: Did ADAMTS13 activity remain below or fall below the expected level after dosing? Was sampling timed appropriately? Is there a pattern across repeat measures?
• Clinical coherence: Did thrombocytopenia, haemolysis or organ manifestations recur in a pattern compatible with TTP? Were competing diagnoses assessed?
• Exposure and adherence: Were doses received as intended? Was there a gap, interruption, administration error or change in dosing interval?
• Dechallenge and intervention: Did activity or clinical status change after treatment modification, inhibitor-directed management, or alternative ADAMTS13 exposure? Rescue treatment is a potential confounder, so response after multiple interventions cannot be attributed to one alone.
• Alternative causes and baseline immunity: Was the patient previously exposed to plasma-derived ADAMTS13? Is acquired anti-ADAMTS13 autoimmunity or another relevant condition in the differential? What can the assay establish about origin?

Causality may remain indeterminate even where the safety concern is medically credible. If the patient has a serious exacerbation and a reported neutralising antibody, the event merits serious consideration while the assessment documents uncertainty about induction, mechanism and assay specificity. “Possible association with treatment; antibody origin cannot be determined by the available assay” may be more accurate than either a definitive causal statement or dismissal as unrelated.

The same distinction applies at aggregate level. A plausible mechanism and a small number of serious cases can justify escalation and regulatory action without a stable estimate of risk. A cluster of cases with confirmed functional inhibition, reduced enzyme activity and compatible disease relapse would strengthen coherence. Conversely, a set of low-titre binding results with no effect on activity or outcomes should not be combined uncritically with inhibitor-associated clinical failures as if they represented one phenotype.

Reporting, Coding and Medical Review

Case processing must follow applicable jurisdictional requirements and the organisation's current procedures. The reporting clock should not be delayed while the MAH seeks antibody titres or adjudication. Where the report identifies a serious cTTP event, its seriousness is assessed using the relevant criteria for the clinical outcome. A binding antibody result alone does not automatically establish a serious adverse reaction; an antibody associated with clinically significant loss of effect may contribute to seriousness depending on consequences such as hospitalisation, life-threatening disease, disability or death.

Narrative and coding should distinguish the reported medical event from its suspected mechanism. For example, a case may contain “acute cTTP exacerbation,” “thrombocytopenia,” “reduced ADAMTS13 activity,” “anti-ADAMTS13 binding antibodies” and “neutralising antibodies detected” as separate facts or diagnoses. Coding should not imply that a neutralising inhibitor was laboratory-confirmed if the source describes only binding antibodies. Use the current MedDRA version and applicable coding conventions, and retain laboratory values and assay details in the narrative or structured fields as supported.

Medical review should assess the event with product, batch, dose and timing information available. If the report mentions a batch or suspected product-quality issue, the relevant quality pathway may need parallel assessment; it does not replace case processing. A suspected loss of efficacy may also require review by clinical, regulatory, quality, medical-information and risk-management teams. The reason for escalation and the information shared should be documented.

Monitoring: What the Label Says and What the PV System Should Track

The US label requires assessment of ADAMTS13 activity and neutralising antibodies before treatment initiation and periodically during the course for all patients, whether previously exposed or naïve to plasma-based products.[3] This is a US prescribing requirement, but the text does not give a fixed interval or specify a universal assay schedule. Those details should not be added to the label by a PV article or company call script. A treating specialist determines the patient's testing and management consistent with the label and clinical context.

The EU SmPC states that antibodies may decrease response and advises consideration of other therapeutic strategies where antibodies are suspected and lack of efficacy is present.[2] The cited current SmPC does not contain the US all-patient testing instruction. EU pharmacovigilance teams should not present the US label's precise monitoring language as a European legal obligation. They should nevertheless collect and evaluate relevant activity, antibody and clinical data in individual reports and in aggregate safety review.

For pharmacovigilance, the key monitoring question is whether the safety system detects clinically meaningful loss of effect and whether available laboratory data are interpretable. Case review can track the presence and timing of ADAMTS13 activity, antibody assay results, clinical events, management and outcome. Signal governance can consider whether the data reveal subgroups or timing patterns that may inform regulators or future risk minimisation. These are evidence-generation and safety oversight activities, distinct from instructing clinicians how often to test.

Lessons for immunogenicity surveillance of other recombinant proteins

The rADAMTS13 signal is product- and disease-specific. It should not be used to claim that neutralising antibodies are a class effect of recombinant proteins or that the observed reports predict a similar event rate for another molecule. The transferable lesson is methodological: immunogenicity surveillance should distinguish binding from neutralising activity, relate test results to exposure and sampling time, assess whether the assay can detect the clinically relevant function, and connect laboratory findings to pharmacokinetic, pharmacodynamic and clinical outcomes. The meaning of an antibody result depends on the protein's biological role and the disease consequences if that role is reduced. For rADAMTS13 in cTTP, reduced enzyme function has a direct pathway to recurrence of a life-threatening disease; another therapeutic protein may have a different exposure-response relationship and different clinical consequences.

For a recombinant protein, case and aggregate review should also consider manufacturing and product comparability information when relevant, alongside dose, route, duration, patient factors and concomitant treatment. Any possible quality or process change is a question for documented product-specific assessment, not an assumed explanation for antibody emergence. Across products, the safety conclusion should therefore state what is shared in the surveillance method and what remains specific to the molecule, indication, assay and available evidence.

Signal Evaluation and Risk Governance

An immunogenicity signal should be evaluated with the assay and clinical phenotype in view. A report count can be misleading if it mixes screening-positive binding ADA, confirmed neutralising activity, low enzyme activity without antibodies, and clinical cTTP recurrence. Search strategies should identify variants of antibody terminology and loss-of-effect manifestations, then medical review should establish whether cases meet a coherent case definition. Coding and narrative searches can be complemented by laboratory or clinical data when those are available.

A practical signal evaluation can address the following questions:

1. What was detected? Separate binding ADA from confirmed neutralising antibody; document assay type, confirmation, titre and limitations.
2. What changed biologically? Examine ADAMTS13 activity before and after treatment, considering dose timing and whether the change is reproducible.
3. What happened clinically? Review platelet count, haemolysis, organ involvement, acute or subacute TTP events, rescue therapy and outcomes.
4. How does timing relate? Consider treatment duration, previous exposure, interruptions and time from last dose to sampling or event.
5. How complete is the evidence? Note missing tests, unavailable assay methods, follow-up gaps and whether reports are duplicates.
6. What is the denominator? Review exposure and follow-up data where available, but do not divide spontaneous report counts by estimated use and present the result as an incidence rate without a suitable design.
7. What action is proportionate? Consider continued monitoring, focused follow-up, regulatory discussion, risk communication or a formal study according to the signal's seriousness, strength and uncertainty.

No single threshold should substitute for expert evaluation. The aim is to make the reasoning reproducible: define the event, preserve the evidence quality, assess alternative explanations and state what additional data could change the conclusion. If cases cannot be distinguished from baseline endogenous anti-ADAMTS13 antibodies, that limitation belongs in the signal conclusion and any regulator-facing presentation.

FDA's required studies respond to key evidence gaps. The prospective interventional trial is intended to assess immunogenicity and clinical loss of efficacy; the non-interventional study is intended to contribute real-world safety follow-up for at least 12 months.[5] Study oversight should monitor protocol feasibility in a rare disease, assay harmonisation, exposure and follow-up completeness, clinically relevant endpoints and participant retention. The required study design does not itself prove a causal mechanism; its purpose is to generate evidence that routine reports cannot supply.

Risk governance should maintain clear ownership. Pharmacovigilance evaluates cases and signals; clinical experts interpret the disease and laboratory picture; regulatory affairs tracks local labelling and authority commitments; quality assesses any product complaint or batch concern; and the qualified person responsible for pharmacovigilance (QPPV) or delegated governance body oversees whether the safety system responds effectively. Responsibilities may vary by organisation, but decisions, evidence and escalations should remain traceable.

Illustrative Case

The following example is hypothetical. A child with cTTP receives prophylactic rADAMTS13 for several months. At a follow-up visit, ADAMTS13 activity is lower than expected and platelet count has declined. A screening test reports anti-ADAMTS13 binding antibodies. The child develops neurological symptoms and is admitted for evaluation. A functional assay is ordered, while the clinician initiates urgent management for suspected acute TTP.

The initial pharmacovigilance report should not wait for the functional assay. The event record should capture the known cTTP exacerbation, neurological symptoms, platelet count, rADAMTS13 exposure and timing, measured enzyme activity, the fact that a binding antibody result is available, and the test still pending. It should not state that a neutralising inhibitor caused the event before the result and interpretation are known. Follow-up can later add the assay method, titre, outcome, rescue treatment and any revised diagnosis.

When the functional assay returns positive, medical assessment should still ask what the test can establish about antibody origin, whether activity findings are compatible, whether the sample timing is understood, and what other causes or treatment gaps could have contributed. If the assay cannot distinguish antibodies against recombinant from endogenous ADAMTS13, that limit should remain explicit. At aggregate level, the case may support the known serious signal even when the precise individual causality remains uncertain.

This scenario also shows why outcome matters. An isolated binding ADA finding without activity change or clinical effect is not equivalent to inhibitor-associated loss of response. A serious exacerbation with functional inhibition is a more coherent and clinically important pattern, but it still requires a careful assessment of the full case.

Common Failure Modes and Controls

These are plausible system vulnerabilities, not statements about actual inspection findings. Controls should be proportionate to the MAH's products, territories, partners and safety data.

Inspection and System Oversight

Inspection readiness depends on being able to trace a signal from source information through case processing, medical assessment, aggregate review and regulatory action. Relevant evidence can include case intake forms, query records, assay interpretation guidance, duplicate assessment, signal searches, meeting minutes, local reference safety information, regulatory commitments and follow-up status. An inspector may ask whether the organisation's procedures are capable of identifying a suspected loss-of-effect event even when the reporter does not use the term “neutralising antibody.”

The system should show how teams handle pending results and how follow-up is prioritised without delaying applicable reporting. It should also show how antibody data are categorised, what medical reviewers are expected to assess, and how the company prevents conclusions based solely on a laboratory test. If there are study commitments, oversight should include milestone tracking, data quality, protocol deviations and escalation of emerging findings.

Effectiveness should be judged against the objective. For case intake, a useful indicator may be whether reports of breakthrough TTP include exposure dates, activity measurements and clinical outcomes after appropriate follow-up. For a risk-minimisation activity, distribution completion alone shows reach, not whether the risk was recognised or managed. The applicable monitoring duty in a particular territory derives from that territory's current label or regulatory instruction; company surveillance metrics are an operational control and should not be confused with a new prescriber requirement.

Practical Checklist

• Confirm the exact rADAMTS13 product, batch, dose, administration dates and any missed or delayed doses.
• Capture cTTP history, prior ADAMTS13 exposure and relevant plasma-based treatment history.
• Record clinical manifestations, platelet count, haemolysis markers, organ findings, seriousness and outcome.
• Obtain ADAMTS13 activity measurements with sample date, dose timing, assay and units where available.
• Distinguish a binding ADA result from a confirmed neutralising assay result.
• Record titre, cut-off, confirmation method and laboratory interpretation if available.
• Follow up pending results without delaying required reporting or urgent internal escalation.
• Preserve assay limitations, including inability to determine antibody origin, in the narrative and assessment.
• Assess treatment response, alternative explanations, rescue interventions and changes in disease activity.
• Evaluate individual causality and aggregate signal coherence separately.
• Apply expectedness against the current local RSI and track FDA and EMA actions by jurisdiction.
• Document signal decisions, regulatory commitments, owners, timelines and evidence of follow-through.

Key Takeaways

Neutralising antibodies against ADAMTS13 can plausibly compromise enzyme replacement in cTTP, where loss of enzyme activity may allow serious disease manifestations to recur. The safety outcome is clinically consequential loss of effect, not antibody positivity alone.

The trial database contained binding antibodies without observed clinical impact and no neutralising-antibody cases, but it was too small to rule out a rare post-marketing event. FDA added a boxed warning in September 2026 after serious outcomes, including death, were reported, and required studies because spontaneous reports alone could not answer key questions.

The United States now requires baseline and periodic ADAMTS13 activity and inhibitor monitoring under the current US label. The EU product information has related immunogenicity language but not identical boxed-warning or testing text as of 3 October 2026. Requirements and risk communication must stay territory-specific.

Case quality depends on preserving the distinction among binding ADA, neutralising activity, reduced enzyme activity, breakthrough cTTP and causal attribution. A good PV system processes reports promptly, seeks clinically useful follow-up, states assay limitations, and maintains a traceable path from individual evidence to signal decisions and risk governance.

References

1. European Medicines Agency. Adzynma: European Public Assessment Report (EPAR). Product overview and exceptional-circumstances authorisation. EMA EPAR.
2. European Medicines Agency. Adzynma, INN-rADAMTS13: Summary of Product Characteristics and package leaflet. Product information updated 2 October 2026. Current EU product information PDF.
3. US Food and Drug Administration. ADZYNMA (ADAMTS13, recombinant-krhn) Prescribing Information. Revised September 2026. FDA-approved label.
4. US Food and Drug Administration. FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 Following Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura. Drug Safety Communication, 21 November 2025. FDA communication.
5. US Food and Drug Administration. Safety Labeling Change Order and SLC Notification Letter: Adzynma. May 2026. FDA order.
6. US Food and Drug Administration. FDA Takes Action with New Boxed Warning for Adzynma Enzyme Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura. 23 September 2026. FDA safety communication.
7. Scully M, et al. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine. 2024;390:1584–1596. Article.
8. Scully M, et al. Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial. Blood. 2026. Journal article. PubMed record.
9. European Medicines Agency. **Guideline on good pharmacovigilance practices (GVP), Module VI: Collection, management and submission of reports of suspected adverse reactions to medicinal products. EMA GVP guidance.
10. European Commission. Regulation (EC) No 726/2004, including centralised authorisation and pharmacovigilance provisions. EUR-Lex.

Regulatory Note

Regulatory status and product information were reviewed as of 3 October 2026. The boxed warning and explicit baseline and periodic monitoring language described above are from the US Prescribing Information revised September 2026. The EU product information available from EMA was updated 2 October 2026 and contains different immunogenicity language. FDA safety communications, FDA safety-labeling orders, approved labelling, EMA product information and EMA public assessment material have different purposes and legal effects. Readers should use current local product information and applicable reporting rules; subsequent decisions may change the status described here.